Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Other
Ratios

Arcus Biosciences (RCUS) Leases (2020 - 2022)

Arcus Biosciences has reported Leases over the past 3 years, most recently at $102.1 million for Q3 2022.

  • Quarterly results put Leases at $102.1 million for Q3 2022, up 186.72% from a year ago — trailing twelve months through Sep 2022 was $102.1 million (up 186.72% YoY), and the annual figure for FY2021 was $105.0 million, up 721.28%.
  • Leases for Q3 2022 was $102.1 million at Arcus Biosciences, down from $104.0 million in the prior quarter.
  • Over the last five years, Leases for RCUS hit a ceiling of $105.0 million in Q4 2021 and a floor of $12.2 million in Q1 2021.
  • Median Leases over the past 3 years was $69.1 million (2021), compared with a mean of $63.8 million.
  • Peak annual rise in Leases hit 741.23% in 2022, while the deepest fall reached 186.72% in 2022.
  • Arcus Biosciences' Leases stood at $12.8 million in 2020, then surged by 721.28% to $105.0 million in 2021, then decreased by 2.76% to $102.1 million in 2022.
  • The last three reported values for Leases were $102.1 million (Q3 2022), $104.0 million (Q2 2022), and $103.0 million (Q1 2022) per Business Quant data.